Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings
09:54am, Wednesday, 26'th Apr 2023
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.
BioRad Laboratories (BIO) to Post Q1 Earnings: What's in Store?
08:24am, Monday, 24'th Apr 2023
Bio-Rad Laboratories' (BIO) first-quarter 2023 results are likely to reflect an impressive performance across its Life Science segment, with a gradual reduction in backlogs and an improvement in the s
Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?
12:55pm, Friday, 14'th Apr 2023
Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.
Is BioRad Laboratories (BIO) Stock Outpacing Its Medical Peers This Year?
11:26am, Friday, 14'th Apr 2023
Here is how Bio-Rad Laboratories (BIO) and CRISPR Therapeutics AG (CRSP) have performed compared to their sector so far this year.
Bio-Rad to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023
04:11pm, Wednesday, 12'th Apr 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the
Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now
01:48pm, Tuesday, 11'th Apr 2023
Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.
Analysts Agree Now's The Time To Buy These 10 Promising Stocks
07:30am, Tuesday, 28'th Mar 2023
Finding S&P 500 stocks that analysts agree on is rare. So when you see nearly unanimous agreement on some, that's quite a statement.
The 3 Most Promising Biotech Stocks to Buy Now
09:00am, Tuesday, 21'st Mar 2023
This year the National Institutes of Health is set to request its biggest budget yet for 2024, on the heels of its previous biggest budget in 2023. As the COVID-19 pandemic fades from view, labs will
Wall Street Analysts Predict a 28.56% Upside in Bio-Rad (BIO): Here's What You Should Know
11:29am, Friday, 10'th Mar 2023
The mean of analysts' price targets for Bio-Rad (BIO) points to a 28.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Bio-Rad (BIO) Global Expansion Strong, FX Woe Dents Growth
09:11am, Thursday, 09'th Mar 2023
Bio-Rad (BIO) experiences double-digit currency-neutral core revenue growth in the Americas and Asia in Q4.
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
12:02pm, Friday, 17'th Feb 2023
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Bio-Rad Laboratories, Inc. (BIO) Q4 2022 Earnings Call Transcript
11:13pm, Thursday, 16'th Feb 2023
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q4 2022 Earnings Conference Call February 16, 2023 5:00 PM ET Company Participants Edward Chung - Vice President, Investor Relations Ilan Daskal - Chief Financia
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
06:49pm, Thursday, 16'th Feb 2023
Bio-Rad (BIO) delivered earnings and revenue surprises of -4.06% and 2.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
09:00am, Friday, 06'th Jan 2023
HERCULES, Calif.--( BUSINESS WIRE )--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for t
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
02:11pm, Thursday, 05'th Jan 2023 Zacks Investment Research
Investors are optimistic about Bio-Rad (BIO), led by robust demand in the Life Science and Clinical Diagnostics arms.
